Pramiracetam Research Overview (also known as CI-879, Pramistar, Remen, Neupramir)
Pramiracetam is a synthetic racetam derivative related to piracetam and is often described by commercial sources as being up to 30 times more potent by mass, although this figure is not a clinically validated potency ratio. Preclinical research suggests that it can enhance high-affinity choline uptake in the hippocampus and influence processes involved in learning, memory formation, and consolidation, but human evidence remains limited and it is not an approved treatment for cognitive disorders in many jurisdictions.
What Is Pramiracetam?
Pramiracetam is a synthetic nootropic compound in the racetam family. Chemically, it is a lipophilic derivative of piracetam, and it was developed to produce cognitive effects at substantially lower milligram doses than the parent compound. The substance is also known by the research code CI-879 and has been marketed in some countries under names including Pramistar, Remen, and Neupramir. Its history is associated with European pharmaceutical development and Italian clinical use, particularly through the Pramistar brand, although the compound itself is generally described in the pharmacology literature as having been developed from the piracetam series by pharmaceutical researchers rather than as a traditional Italian medicine.
Pramiracetam is frequently advertised as being up to 30 times more potent than piracetam. This comparison should be interpreted cautiously: it is primarily a dose-equivalence claim based on experimental and commercial descriptions, not a universally accepted clinical measurement. Potency by milligram does not establish superior overall effectiveness, safety, or therapeutic value. Human trials have been relatively small and dated, and much of the mechanistic literature comes from animal or ex vivo studies. Unlike an approved cognitive medication, pramiracetam does not have a well-established evidence-based dosing standard for healthy adults.
The compound is of interest because racetams may influence neuronal membrane function, cholinergic signaling, and plasticity-related processes without acting as classic acetylcholinesterase inhibitors or direct stimulants. Pramiracetam has received particular attention for effects on high-affinity choline uptake, commonly abbreviated HACU, in the hippocampus. HACU is an important step in supplying choline for acetylcholine synthesis, and hippocampal cholinergic activity is closely associated with attention, encoding, and memory. These observations have led to interest in pramiracetam for memory disorders, age-associated cognitive decline, traumatic brain injury, and experimental amnesia.
Nevertheless, the distinction between a plausible mechanism and a demonstrated clinical benefit is important. Evidence does not establish that pramiracetam prevents dementia, reverses Alzheimer's disease, reliably improves intelligence, or produces durable benefits in healthy people. Product quality is also variable because many preparations are sold through supplement or research-chemical channels rather than regulated pharmaceutical systems.
Research Indications
Cognitive Performance
Memory impairment research
Small, older clinical studies evaluated pramiracetam for memory complaints and cognitive impairment. Findings are limited by modest sample sizes and study designs that do not meet current evidentiary standards.
Attention and learning tasks
Preclinical work and limited human research suggest possible effects on learned-task performance and attention, but reliable benefits in healthy adults remain unestablished.
Cholinergic Mechanisms
High-affinity choline uptake
Animal studies have associated pramiracetam exposure with changes in hippocampal high-affinity choline uptake, a process relevant to acetylcholine synthesis.
Membrane and neurotransmitter hypotheses
Proposed actions include effects on neuronal membrane function and cholinergic signaling; these mechanisms remain incompletely characterized in humans.
Neurological Recovery Research
Post-injury cognitive symptoms
Pramiracetam has been explored in older research involving cognitive deficits after neurological injury. Evidence is insufficient to establish clinical effectiveness or safety for this use.
Age-related cognitive decline
Historical studies in older adults are not adequate to support use for dementia, mild cognitive impairment, or age-related cognitive decline outside appropriately supervised research.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Initial tolerability assessment | 150 mg | Once daily | Oral |
| Cognitive research protocol | 300 mg | Once daily | Oral |
| Divided-dose research approach | 200–300 mg | Twice daily | Oral |
| Historical clinical-study range | 600–1,200 mg/day | Divided doses | Oral |
Timing
Research users commonly take oral doses earlier in the day, with or without food according to individual gastrointestinal tolerance. Avoid late-day administration if sleep disruption, restlessness, or headache occurs.
Peptide Interactions
Choline donors such as dietary choline, citicoline, or alpha-GPC are sometimes paired based on cholinergic hypotheses. Human evidence for added benefit or prevention of headache is limited.
A formal interaction is not well defined, but combining agents that affect alertness may increase jitteriness, anxiety, headache, elevated heart rate, or sleep disturbance in sensitive individuals.
Alcohol can impair cognition and coordination and may obscure adverse effects. It is not an appropriate combination for evaluating subjective cognitive response.
Racetam-class compounds have been discussed in relation to platelet effects, although pramiracetam-specific clinical interaction data are sparse. Seek clinician review before combining with warfarin, direct oral anticoagulants, aspirin, or clopidogrel.
No established direct interaction is documented, but medications with anticholinergic activity can independently affect memory, attention, dry mouth, vision, and urinary function.
There are inadequate interaction studies with antidepressants, ADHD medications, antipsychotics, and dementia therapies. Do not alter prescribed treatment without clinician oversight.
Reported Research Timeline
01First dose to several hours (reported in cited studies): some users report subjective alertness or headache; others notice no acute effect. Acute subjective effects are not reliable evidence of cognitive improvement.
02Days 1–3 (reported in cited studies): monitor sleep, mood, appetite, gastrointestinal tolerance, and headache frequency before considering any dose change or additional compounds.
03Week 1 (reported in cited studies): if tolerated, a consistent administration schedule allows a clearer comparison with baseline performance. Expect substantial day-to-day variability in attention and productivity.
04Weeks 2–4 (reported in cited studies): any perceived benefit should be assessed with predefined, repeatable measures rather than impressions alone. High-quality evidence does not establish a predictable response timeline.
05After 4 weeks (reported in cited studies): reassess benefit versus adverse effects with a clinician, particularly when use is intended for cognitive symptoms, neurological illness, or alongside prescription medicines.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Human safety data for pramiracetam are limited, particularly for long-term use, high doses, pregnancy, and combinations with prescription medications.
Reported adverse effects may include headache, insomnia, nervousness, gastrointestinal upset, dizziness, or fatigue; frequency and causality are not well quantified.
Avoid use during pregnancy or breastfeeding unless specifically directed by a qualified clinician; developmental and reproductive safety data are inadequate.
People with kidney disease, seizure disorders, bleeding disorders, or major psychiatric illness should obtain medical advice before use.
Do not use pramiracetam as a substitute for evaluation of new, progressive, or disabling memory and concentration changes.
Seek Medical Attention If:
You develop signs of an allergic reaction, including facial or throat swelling, wheezing, hives, or difficulty breathing.
You experience chest pain, fainting, severe palpitations, severe agitation, confusion, or a marked change in mood or behavior.
You have unusual bleeding, black stools, vomiting blood, or extensive unexplained bruising, especially when taking anticoagulant or antiplatelet medication.
A severe or persistent headache occurs with neurological symptoms such as weakness, vision change, speech difficulty, or seizure activity.
Quality Indicators
Verified Marker
Lot-specific certificate of analysis
Look for a recent COA tied to the exact lot number, identifying pramiracetam and reporting assay results rather than a generic template.
Verified Marker
Independent identity and purity testing
Prefer third-party testing using an appropriate method such as HPLC or LC-MS, with a stated purity result and laboratory identification.
Verified Marker
Heavy-metal and microbiological screening
For finished oral products, documentation should include contaminant screening for heavy metals and, where relevant, microbial limits.
Acceptable Range
Accurate capsule or serving declaration
The label should clearly state milligrams of pramiracetam per capsule or scoop, excipients, suggested storage, and a traceable manufacturer or distributor.
Quality Concern
Unverifiable purity or implausible claims
Avoid products without lot-specific documentation, products sold only with “research grade” claims, or products promising treatment of dementia, ADHD, or neurological disease.
Research Citations
- Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders
Malykh, A. G., Sadaie, M. R., et al., 2010, Drugs - Clinical efficacy of piracetam in cognitive impairment: a meta-analysis
Waegemans, T., Wilsher, C. R., Danniau, A., et al., 2002, Dementia and Geriatric Cognitive Disorders - Piracetam: a review of pharmacological properties and clinical uses
Winblad, B., 2005, CNS Drug Reviews - Piracetam: novelty in a unique mode of action
Müller, W. E., Eckert, G. P., Eckert, A., et al., 1997, Pharmacopsychiatry
Research Focus
memory consolidation, HACU enhancement, Alzheimer's, cognitive decline, LTP
Frequently Asked Questions
What should researchers watch for with Pramiracetam?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with Pramiracetam?
First dose to several hours (reported in cited studies): some users report subjective alertness or headache; others notice no acute effect. Acute subjective effects are not reliable evidence of cognitive improvement.
How is Pramiracetam typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →